Cipher Pharmaceuticals (CPHR) Earns News Sentiment Rating of 0.11
News coverage about Cipher Pharmaceuticals (NASDAQ:CPHR) (TSE:CPH) has been trending somewhat positive recently, according to Accern Sentiment. Accern identifies positive and negative press coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Cipher Pharmaceuticals earned a daily sentiment score of 0.11 on Accern’s scale. Accern also gave news stories about the company an impact score of 45.4097263665194 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the near term.
Cipher Pharmaceuticals (NASDAQ:CPHR) remained flat at $2.99 during mid-day trading on Friday. The firm has a 50 day moving average price of $3.37 and a 200 day moving average price of $3.08. Cipher Pharmaceuticals has a 1-year low of $2.55 and a 1-year high of $4.22.
COPYRIGHT VIOLATION WARNING: This news story was originally published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this news story on another publication, it was illegally stolen and reposted in violation of United States and international copyright & trademark law. The correct version of this news story can be viewed at https://www.thecerbatgem.com/2017/09/16/cipher-pharmaceuticals-cphr-earns-news-sentiment-rating-of-0-11.html.
About Cipher Pharmaceuticals
Cipher Pharmaceuticals Inc is a specialty pharmaceutical dermatology company. The Company has a portfolio of commercial and late-stage products. It operates in the specialty pharmaceuticals segment. It acquires products and compounds for treatment of various medical needs. Its commercial product portfolio includes ABSORICA; SITAVIG; NUVAIL; BIONECT; CLN8; INOVA; PRO:12 MOUSSE; AL12; LOTION UMECTA; ACLARO; EPURIS; VANIQA; ACTIKERALL; BETEFLAM; LIPOFEN; CONZIP, and DURELA.
Receive News & Stock Ratings for Cipher Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cipher Pharmaceuticals Inc and related stocks with our FREE daily email newsletter.